Back to Results
First PageMeta Content
Pharmacology / Pharmaceuticals policy / Clinical pharmacology / Medical prescription / Patient safety / Pharmacist / Ambrisentan / Prescription medication / Pregnancy / Medicine / Health / Chemistry


NDA[removed]LetairisÒ (ambrisentan) RISK EVALUATION AND MITIGATION STRATEGY (REMS)
Add to Reading List

Open Document

File Size: 4,63 MB

Share Result on Facebook

City

Reference / Foster City / /

Company

Gilead Sciences Inc. / /

Facility

Letairis REMS Coordinating Center / /

IndustryTerm

daily product / licensed healthcare professionals / Healthcare providers / food / /

MedicalCondition

pulmonary arterial hypertension / serious birth defects / nasal congestion / high blood pressure / sinusitis / tiredness / anemia / /

MedicalTreatment

birth control / emergency contraception / contraception / blood transfusion / /

Organization

FDA / Letairis REMS Coordinating Center / /

/

Position

Counsel / physician / designated representative / /

Product

Sandimmune / Neoral / cyclosporine / Gengraf / REMS ELEMENTS A. Medication / Letairis / /

ProvinceOrState

California / /

PublishedMedium

the Letairis REMS Program Guide / the Prescriber Guide / The Medication Guide / the Letairis Medication Guide / /

URL

www.letairisrems.com / /

SocialTag